Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. - Wikidata - wikimedia - TriplyDB

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

http://www.wikidata.org/entity/Q37375819

about

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce Current and emerging treatment options for patients with relapsed myeloma Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers Salvage second hematopoietic cell transplantation in myeloma Durable remission with salvage second autotransplants in patients with multiple myeloma.Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.Current multiple myeloma treatment strategies with novel agents: a European perspective Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Relapsed multiple myeloma: who benefits from salvage autografts?Second autologous transplant as salvage therapy in multiple myeloma.Choosing treatment options for patients with relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Treatment of Relapsed/Refractory Multiple Myeloma.Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.Second auto-SCT for treatment of relapsed multiple myeloma.Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma.Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.When to recommend a second autograft in patients with relapsed myeloma?Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

P2860

Q26782868-54AF9BD9-822E-45F8-A5B1-CDF6640E7F6E Q26830878-A02076E2-9211-4CA5-B078-D6652EFC68B9 Q26851202-1277335E-C32A-44FF-8E03-2D9B2D91A8F3 Q30416452-6F5DD396-67B4-4038-969E-300A1C3CF08C Q33685400-EC6D66E1-F77A-48F6-8C35-C54E05A6B9D2 Q36138646-71B847A0-9D90-4BBF-BE5D-B7EA37C314D0 Q36612669-08315CB1-B716-4515-9840-B277A8D3EB62 Q36834629-71AE01FC-9EE8-4A86-B41C-0D0DFB6CC809 Q37627044-7FEC88A2-E815-4C45-A97F-6073B6539ECD Q37677935-CCD0EAF9-28F4-471B-9E34-27A76B12EF7A Q37829230-66F441ED-9047-4571-8A16-B6DAAE52C4D4 Q37949201-7B51C310-05E0-4D6E-8219-32AA69A4C945 Q38023515-330F5B48-9BA8-4EA6-8693-892C173D54F9 Q38151157-CB264E4C-7AC6-4C5E-B3B3-FD618EB6B838 Q38170453-0D14DE18-FD24-4050-94AE-0E3273CB4FED Q38261677-BDABBEA8-27D0-4B76-AAF5-8EA5D6C88AFF Q38370539-F5451178-1A07-4423-B7C5-14D4AD623EB4 Q38970597-6F2DFD87-7963-4ED3-AEED-AA373A06B88B Q44385832-9EB33782-0B27-4343-8FDB-125227D33C28 Q44647283-BE654101-33E3-48A7-B018-383CFD0E287B Q44758991-F7C2FFEF-0DC0-400A-97A8-54A81E2261BF Q45918038-9881EE5C-32ED-472D-9D2B-3DD320A77729 Q47149240-A81778B5-CE57-4BB9-82C4-DE401903B007 Q47196540-B7941710-BB87-490B-B8EA-041346AE97D8 Q48139344-8BAEDA85-4287-4668-80C8-F7F0061FE722 Q48250743-FE74BA1C-B4F6-4406-B07C-47158A193457 Q48921667-BF3A98DC-E9E8-4577-868B-1C3DA7B06FEB Q50438558-86BEEFDC-65A0-4AA4-A408-A7F1FFDBDE43 Q53112373-A3FD568B-80A2-447C-A3FA-37B5C6A1F738

P2860

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

http://www.wikidata.org/entity/Q37375819

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@en

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@nl

type

label

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@en

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@nl

prefLabel

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@en

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@nl

P1433

Q37375819-FE29404C-FBF5-4327-A832-A1C17AA580E8

P1476

Q37375819-41F6000D-C202-43F1-89F8-473C96143688

P2093

Q37375819-1692E595-9E18-442C-AA1A-0A83B3CFB709

Q37375819-3D07608D-DEB0-4B0D-A5A7-E9C79C434CCB

Q37375819-3DD4EA42-69C4-4362-89B6-43245DCE61AA

Q37375819-45E06142-3B23-4D94-95CE-0298A9A92F96

Q37375819-57A9AE8A-76B9-44B9-BD59-D8F39B1F32A2

Q37375819-7A834EE6-B7EC-4843-9816-8B466FBFD146

Q37375819-9E8EB9F2-3DEC-4FCE-958B-485561954773

Q37375819-CCDF8316-9DCD-4065-9B39-CE6B73BAE641

Q37375819-D4309F57-E77F-4E3F-A53D-387EE359934B

Q37375819-EC23D438-801B-4E01-BCF5-25ED92D1B0BB

P2860

Q37375819-158B8D62-A5A5-4990-B020-C92B87580FF0

Q37375819-2F020F1B-FFEC-488E-B709-174D57AC3D94

Q37375819-41AE2F6A-B167-40A5-9106-7E6804A3AEBD

Q37375819-5FB14149-ACE8-4504-923D-04356DBEFF14

Q37375819-6E99085D-83E9-44EE-B803-EE95729A8F02

Q37375819-748925C7-5825-47C7-8750-7C9CC1018ED0

Q37375819-7567C635-7C52-4444-AD2E-E605B856D492

Q37375819-7F0BA964-33BA-4D54-B7AA-F05FD2E944DE

Q37375819-B4E764EC-685A-49B6-95BD-E00649492295

Q37375819-D7EEA1EA-CCE8-4D21-8D96-F5F5B956C889

P2888

Q37375819-C0D86A2E-8770-4BD6-92B6-ACEBD9A54D2A

P304

Q37375819-E430B460-43D9-4199-96E8-A15566AAB7A2

P31

Q37375819-E073769A-1B1B-4567-BFB6-68CB65B0473D

P356

Q37375819-75D3D8F6-9819-49D8-9FDE-9C81B5FFD996

P407

Q37375819-37FCDE7C-C6B6-40B9-B54B-2F7A29A958AE

P433

Q37375819-4E4AE5A3-1F44-4A11-81D7-2FE2111B582E

P478

Q37375819-94F84481-E326-4F1C-AB5B-713BE2D61971

P577

Q37375819-74FFD45F-2256-4195-B690-80191C3588D1

P5875

Q37375819-B05FE75A-4F34-428E-84A2-2A0A9A8D20EE

P6179

Q37375819-2A7B1D7F-43DC-40E3-824E-2A63E84E23F9

P698

Q37375819-62F693C2-D493-4EAA-8159-C8FE3A220F62

P932

Q37375819-8A3F2F04-9882-496C-B194-D76A9D8B556A

P356

P1433

Bone Marrow Transplantation

P1476

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.

@en

P2093

D E Tsai

http://www.w3.org/2001/XMLSchema#string

D L Porter

http://www.w3.org/2001/XMLSchema#string

D L Siegel

http://www.w3.org/2001/XMLSchema#string

D T Vogl

http://www.w3.org/2001/XMLSchema#string

E A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

K Cunningham

http://www.w3.org/2001/XMLSchema#string

P A Mangan

http://www.w3.org/2001/XMLSchema#string

R J Cook

http://www.w3.org/2001/XMLSchema#string

R L Olin

http://www.w3.org/2001/XMLSchema#string

S J Schuster

http://www.w3.org/2001/XMLSchema#string

P2860

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

International uniform response criteria for multiple myeloma.

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.

Management of multiple myeloma: the changing landscape.

Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.

The role of second autografts in the management of myeloma at first relapse.

Single versus double autologous stem-cell transplantation for multiple myeloma.

Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial.

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

P2888

P304

417-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2008.334

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23312356

http://www.w3.org/2001/XMLSchema#string

P6179

1021521647

http://www.w3.org/2001/XMLSchema#string

P698

18850013

http://www.w3.org/2001/XMLSchema#string

P932

2757257

http://www.w3.org/2001/XMLSchema#string